The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open accessPublished version of a preprint
Abstract
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies. Overall, 37.1% (319/860) of patients received a matched therapy guided by their tumor molecular profile. Excluding alterations associated with standard-of-care therapy, 14.4% (69/478) received matched therapy, with a clinical benefit of 52%. Use of matched therapy was strongly influenced by the level of preexistent clinical evidence that the mutation identified predicts for drug response. Analysis of genes mutated significantly more often in tumors without known actionable mutations nominated STK11 and KEAP1 as possible targetable mitogenic drivers. Significance: An increasing number of therapies that target molecular alterations required for tumor maintenance and progression have demonstrated clinical activity in patients with lung adenocarcinoma. The data reported here suggest that broader, early testing for molecular alterations that have not yet been recognized as standard-of-care predictive biomarkers of drug response could accelerate the development of targeted agents for rare mutational events and could result in improved clinical outcomes. Cancer Discov; 7(6); 596–609. ©2017 AACR. See related commentary by Liu et al., p. 555. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [21]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Somatic mutations in LKB1 and KEAP1 significantly co-occur with mutant KRAS and with each other in NSCLC15, 59, 63, 91.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Although EGFR –mutant tumors represent the prototypical oncogene-addicted LUAD subgroup that spearheaded adoption of the single-driver model, the overwhelming majority of EGFR-mutant lung tumors harbor one or more co-mutations, even when the analysis is limited to pre-defined sets of cancer-relevant genes within established panels (FoundationOne, Guardant360, MSK-IMPACT)15, 59, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
Research works printed but not linked: 2
- OncoKB.org, 2016, Precision Oncology Knowledge Base [Internet]
- Banno, 2016, : 10.1111/.12980, Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?, Cancer Sci · DOI
Cited by
Sorted by citations
Items 401–500 of 645
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 6
Zhong, Y., Li, M., Guo, S., Li, M., Cao, Z., Luo, X., Liu, J., Liang, R., Shao, Y., Yang, Y., et al. (2023) · Journal of Oncology · doi:10.1155/2023/2745074 · Cited by 6
Chen, X., Li, D., Miao, K., Shou, T., & Zhang, W. (2023) · Medicine · doi:10.1097/md.0000000000032697 · Cited by 6
Ju, S., Cui, Z., Hong, Y., Wang, X., Mu, W., Xie, Z., XueXia, Z., Su, L., Lin, X., Zhang, Z., et al. (2023) · Cancer · doi:10.1002/cncr.34804 · Cited by 6
Lung cancer treatment potential and limits associated with the STAT family of transcription factors
Faida, P., Attiogbe, M. K. I., Majeed, U., Zhao, J., Qu, L., & Fan, D. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110797 · Cited by 6
Lee, M. H., Liu, J., Miao, E., Wang, S., Zhang, L., Wei, J. X., Chung, J., Xue, X., Halmos, B., Hosgood, H. D., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7064 · Cited by 6
About molecular profile of lung cancer in Tunisian patients
Mezni, F. E., Mlika, M., Boussen, H., Ghédira, H., Fenniche, S., Talmoudi, F., & Loriot, M. (2018) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2017.1407339 · Cited by 6
Fallet, V., Matton, L., Schernberg, A., Canellas, A., Cornélis, F., & Cadranel, J. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1152 · Cited by 6
Choong, W.-K., & Sung, T. (2021) · iScience · doi:10.1016/j.isci.2021.102522 · Cited by 6
Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice – The Welsh Experience
Cox, S., Powell, C., & Morgan, S. W. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.08.025 · Cited by 6
Qi, W., Xi, D., Bai, Y., Liu, L., Ma, Y., Yin, Z., & Chen, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1026135 · Cited by 6
D′Souza, G., Dhar, C., Kyalanoor, V., Yadav, L., Sharma, M., Mohammad Nawaz, S., & Srivastava, S. (2020) · Cancer Reports · doi:10.1002/cnr2.1262 · Cited by 6
Sepúlveda-Hermosilla, G., Blanco, A., Freire, M., Lizana, R., Cáceres-Molina, J., Ampuero, D., Pérez, P., Ramos, L., Aren, O. R., Chernilo, S., et al. (2020) · medRxiv · doi:10.1101/2020.09.11.20171025 · Cited by 6
Chen, K.-T., Sethunath, V., Ebot, E. M., Decker, B. J., Gascó, A., Ross, J. S., Heilmann, A. M., Smith, S., Lofgren, K. T., & Huang, R. S. P. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf390 · Cited by 5
Huang, H.-C., Deng, Q., Guo, L., Gorría, T., Pecci, F., Yang, D., Rodig, S. J., Casas, L. E. D. L., Hallin, J. F., Christensen, J. G., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6647 · Cited by 7
Gu, G., Liu, C., Zhu, X., Yang, Y., Song, S., Zhao, Y., & Sun, G. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05932-x · Cited by 7
Takeda, M., Ota, M., Iwama, E., Sugawara, S., Shukuya, T., Umemura, S., Tanaka, H., Oki, M., Takahama, T., Masuda, T., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.12.004 · Cited by 5
A newly developed capture-based sequencing panel for genomic assay of lung cancer
Im, S.-W., Chae, J., Jang, S. S., Choi, J., Yun, J., Cha, S., Kwon, N., Jeon, Y. K., Hwang, Y., Kim, M., et al. (2020) · Genes & Genomics · doi:10.1007/s13258-020-00949-1 · Cited by 5
Yang, M., Vioix, H., Sachdev, R., Stargardter, M., Tosh, J. C., Pfeiffer, B. M., & Paik, P. K. (2022) · Value in Health · doi:10.1016/j.jval.2022.11.018 · Cited by 5
Self-citationNaso, J. R., Lo, Y., & Sholl, L. M. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27184 · Cited by 5
Elahi, A. H., Morales, C. S., Xu, X. L., Eliades, A., Patsalis, P. C., Abramson, D. H., & Jhanwar, S. C. (2023) · Advances in Biological Regulation · doi:10.1016/j.jbior.2023.100964 · Cited by 5
Tschernichovsky, R., Averbuch, I., Goldstein, D. A., Mutai, R., Dudnik, E., Rotem, O., Geva, S., Peled, N., Goldberg, Y., & Zer, A. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-594 · Cited by 5
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia
Ngo, P., Karikios, D. J., Goldsbury, D. E., Wade, S. L., Lwin, Z., Hughes, B. G. M., Fong, K. M., Canfell, K., & Weber, M. F. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01291-6 · Cited by 6
Plomer, E., Früh, M., Lauber, A., Demmer, I., Jochum, W., & Koster, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115698 · Cited by 4
van Schaik, L. F., Engelhardt, E. G., Wilthagen, E. A., Steeghs, N., Coves, A. F., Joore, M. A., van Harten, W. H., & Retèl, V. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104441 · Cited by 5
Guo, Y., Zhang, R., Meng, Y., Wang, L., Zheng, L., & You, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1359403 · Cited by 5
Peng, M.-H., Huang, Y.-H., Hsu, K.-H., Tseng, J., Lee, P.-H., Chen, K., Chang, G., & Yang, T. (2024) · Cancers · doi:10.3390/cancers16244174 · Cited by 5
Occhipinti, M. A., Imbimbo, M., Ferrara, R., Simeon, V., Fiscon, G., Marchal, C., Skoetz, N., & Viscardi, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015140.pub2 · Cited by 6
Precision Medicine in Lung Cancer
Joshi, E., Nanayakkara, B., Barnes, D. J., & Troy, L. K. (2020) · EMJ Oncology · doi:10.33590/emjoncol/19-00145 · Cited by 5
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy
Bronte, G., Cafaro, A., Pasini, L., Priano, I., Andrikou, K., Cravero, P., Burgio, M. A., Delmonte, A., & Crinò, L. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1923485 · Cited by 5
Sharma, M., Nathany, S., & Batra, U. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_85_21 · Cited by 5
Sun, Q., Li, W., Liu, T., & Guo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.916681 · Cited by 5
Workman, S., Jabbour, S. K., & Deek, M. P. (2023) · AME Medical Journal · doi:10.21037/amj-2022-01 · Cited by 6
Lin, X., Yang, S., Zhou, C. M., Ao, C., & Sun, D. (2023) · Medical Oncology · doi:10.1007/s12032-023-02162-y · Cited by 5
How sustainable are new treatment strategies for NSCLC?
Remón, J., Lopes, G. D. L., Jr., & Camps, C. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30184-5 · Cited by 5
Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR
Zhang, X., Jiang, W., Yang, N., & Zhang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.002 · Cited by 5
Vadagam, P., Waters, D. D., Bhagat, A., Kuang, Y., Uyei, J., & Vanderpoel, J. (2025) · Current Oncology · doi:10.3390/curroncol32040191 · Cited by 4
Le, X., Popat, S., Heymach, J. V., West, H., & Zhang, L. F. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106027 · Cited by 4
Zhou, H., Zhao, H., Hou, X., Wang, Y., He, Z., Li, Y., Ma, Y., Zhao, Y.-H., Huang, Y., Chen, L., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01929 · Cited by 4
Ura, A., Hayashi, T., Komura, K., Hosoya, M., Takamochi, K., Sato, E., Saito, S., Wakai, S., Handa, T., Saito, T., et al. (2023) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.350 · Cited by 4
Vigdorovits, A., Olteanu, G., Paşcalău, A. V., Pîrlog, R., Berindan‐Neagoe, I., & Pop, O. L. (2024) · Diagnostics · doi:10.3390/diagnostics14232660 · Cited by 4
Bote, H., Siringo, M., Conde, E., Hernández, S., López‐Ríos, F., Castelo-Loureiro, A., García-Lorenzo, E., Baena, J., Herrera, M., Enguita, A. B., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100778 · Cited by 4
Advanced Biomarkers and Precision Medicine: Innovative Strategies to Prevent Cancer Recurrence
Shankar Ganesh, M., Revanth, R., & Bharathi, C. M. E. (2025) · Journal of cancer research updates · doi:10.30683/1929-2279.2025.14.01 · Cited by 4
The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma
Guo, L., Yi, J., Liu, M., & Li, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1852 · Cited by 4
Gu, G., Yu, B., Wan, H., Lu, S., Zhu, X., Zhao, Y., Fuxi, Y., & Liu, C. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s381825 · Cited by 5
Huang, Y., Guo, J., Li, S., Liu, J., Xu, J., Ye, W., Zhang, L., Dong, Z., Wu, W., Wu, C., et al. (2022) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001060 · Cited by 4
Shiraishi, T., Yamasaki, K., Kidogawa, M., Shingu, T., Ujimiya, F., Jotatsu, T., Matsumoto, S., Izumi, H., Nishida, C., Goto, K., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1164-22 · Cited by 4
Nkosi, D., George, G. V., Liu, H., Buldo, M., Velez, M. J., & Oltvai, Z. N. (2023) · Genes · doi:10.3390/genes14081551 · Cited by 4
Arnon, J., Tabi, M., Rottenberg, Y., Zick, A., Blumenfeld, P. A., Hamburger, T., Pikarsky, E., Avraham, E., Levine, L., Popovtzer, A., et al. (2023) · Cancers · doi:10.3390/cancers15194733 · Cited by 4
Cho, D., Lord, S. J., Ward, R. L., IJzerman, M. J., Mitchell, A., Thomas, D. M., Cheyne, S., Martin, A. J., Morton, R. L., Simes, J. R., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241273062 · Cited by 4
Shim, J. S. G., Kim, Y., Yuh, T., Lee, J. B., Kim, H. R., Hong, M. H., Cho, B. C., & Lim, S. M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s485320 · Cited by 4
Self-citationHuang, Y., Zeng, H., Zhang, G., Ren, F., Yuan, Z., Ren, J., Xu, J., Song, Z., Li, W., Ying, J., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16528-7 · Cited by 4
Suryanto, R., Widiastuti, H., Sofyani, H., Murtin, A., Yani, I., Thamrin, D. A. F., & Utami, T. P. (2025) · Multidisciplinary Science Journal · doi:10.31893/multiscience.2025360 · Cited by 4
Updates in Lung Cancer Cytopathology
VanderLaan, P. A. (2018) · Surgical pathology clinics · doi:10.1016/j.path.2018.04.004 · Cited by 4
KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations
Rothschild, S. I. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.004 · Cited by 5
Cellular processes involved in lung cancer cells exposed to direct current electric field
Li, H., Liu, S., Yang, X., Du, Y., Luo, J., Tan, J., & Sun, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-62332-0 · Cited by 4
Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
Zhou, W., Yan, L.-D., Yu, Z.-Q., Li, N., Yang, Y., Wang, M., Chen, Y., Mao, M.-X., Peng, X., & Cai, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13301 · Cited by 4
Mazzaschi, G., Perrone, F., Minari, R., Verzè, M., Azzoni, C., Bottarelli, L., Pluchino, M., Armillotta, M. P., Ubaldi, A., Altimari, A., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.005 · Cited by 4
Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
Bae, K., Kim, J. H., Lee, J. Y., Kong, S., Kim, Y., Kim, S., & Yoon, K. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.952651 · Cited by 4
Mfumbilwa, Z. A., Wilschut, J. A., Simons, M., Ramaekers, B. L. T., Joore, M. A., Retèl, V. P., der Welle, C. M. C., Schramel, F. M. N. H., van de Garde, E. M. W., & Coupé, V. M. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-29286-5 · Cited by 4
Lai, L., Ren, Y., Huai, Y., Liu, Y., Liu, Y., Wang, S., & Mei, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1139994 · Cited by 4
An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health
Ghosh, S., Bhuniya, T., Dey, A., Koley, M., Roy, P., Bera, A., Gol, D., Chowdhury, A., Chowdhury, R., & Sen, S. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04748-8 · Cited by 5
Metro, G., Baglivo, S., Moretti, R., Bellezza, G., Sidoni, A., & Roila, F. (2020) · Oncology and Therapy · doi:10.1007/s40487-020-00121-5 · Cited by 4
Metro, G., Giglio, A. D., Ricciuti, B., Siringo, M., Marinelli, D., Gelibter, A. J., Pecci, F., Berardi, R., Cantini, L., Federico, A. D., et al. (2022) · Drugs in Context · doi:10.7573/dic.2022-3-9 · Cited by 4
Mazzotta, M., Filetti, M., Rossi, A., Roberto, M., Occhipinti, M. A., Pernazza, A., Napoli, A. D., Scarpino, S., Vecchione, A. M., Giusti, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.016 · Cited by 4
Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC
Dagogo‐Jack, I., & Lennerz, J. K. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.019 · Cited by 4
Yu, N., Hwang, M., Ahn, B., Lee, Y., Hong, S. H., Sim, H., Song, B., Kim, S., Park, C., & Han, J. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01493-2 · Cited by 3
Carbone, M., Amos, C. I., Attanoos, R. L., Boeri, M., Bueno, R., Bunn, P. A., Chirieac, L. R., Cooper, B. T., Fennell, D. A., Galateau-Sallé, F., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.002 · Cited by 4
Self-citationFebres‐Aldana, C. A., Vanderbilt, C., Aly, R. G. M., Saliba, M., Seshan, S. V., Frosina, D., Jungbluth, A. A., Richards, A. L., Bodd, F. M., Wilson, C., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.100965 · Cited by 4
Self-citationA richer understanding of intratumoral heterogeneity: single-cell genomics put it within reach
Li, X., & Hou, J. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.17 · Cited by 3
Wang, G., Zheng, H., Zhao, X., Wang, Y., Zeng, Y., & Du, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.756772 · Cited by 3
Dhamelincourt, E., Descourt, R., Rousseau-Bussac, G., Doubre, H., Decroisette, C., Demontrond, P., Garff, G. L., Falchero, L., Huchot, E., Vieillot, S., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01014-z · Cited by 3
Cao, Y., Yi, H., Shi, F., Wei, X., & Han, S. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01761-7 · Cited by 3
Chan, S. W. S., Zeng, J., Young, J., Barghout, S. H., Al-Agha, F., Raptis, S., Brown, M. C., Liu, G., Juergens, R. A., & Jao, K. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.10.009 · Cited by 3
The therapeutic potential of RNA m(6)A in lung cancer
Yu, J., Wei, S., Zhao, X., & Chen, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01980-5 · Cited by 3
Mével‐Aliset, M., Radu, A. G., Allard, J., Blanchet, S., Montellier, E., Hainaut, P. L., Rossignol, R., Torch, S., Orsi, G. A., & Thibert, C. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151571 · Cited by 3
Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation
Faehling, M., Fallscheer, S., Schwenk, B., Seifarth, H., Sträter, J., Lengerke, C., & Christopoulos, P. (2025) · Cancers · doi:10.3390/cancers17071237 · Cited by 3
Zhang, L., Huang, Y., Gan, X., He, S., Cheng, X., Yang, N., Li, S., Li, Z., & Zheng, F. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190712203217 · Cited by 3
STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
Kelly, A. D., Wiklund, T. A., Kononen, J., & Creeden, J. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00142 · Cited by 3
Hanrahan, A. J., Iyer, G., & Solit, D. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00002-5 · Cited by 5
Self-citationMorfouace, M., Novello, S., Stevovic, A., Dooms, C., Janžič, U., Berghmans, T., Dziadziuszko, R., Gorlia, T., Felip, E., Paz-Ares, L. G., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12056-0 · Cited by 3
Cho, D., Cheyne, S., Lord, S. J., Simes, R. J., & Lee, C. K. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058350 · Cited by 3
Jesinghaus, M., Boxberg, M., Schmitt, M. P., Kriegsmann, M., Harms, A., Lang, C., Muley, T., Winter, H., Kriegsmann, K., Warth, A., et al. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.295 · Cited by 3
Cho, H. J., Hong, S. A., Ryu, D., Hong, S. H., & Kim, T. (2022) · Cancers · doi:10.3390/cancers14225600 · Cited by 3
Hashimoto, T., Owada, Y., Katagiri, H., Yakuwa, K., Tyo, K., Sugai, M., Fuzimura, I., Utsumi, Y., Akiyama, M., Nagashima, H., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-15 · Cited by 2
Oi, I., Ito, T., Saito, Z., Imakita, T., Kanai, O., Fujita, K., Tachibana, H., & Mio, T. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15171 · Cited by 2
Shah, R., Alex, D., & Xu, Z. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.16.2.100 · Cited by 3
Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience
Refae, A. A., Bayer, A. M., Ibrahim, E. M., Mansoor, I., Saleem, N. A., Al-Masri, O. A., Shakra, R. I. A., & Wm, E. (2019) · Annals of Clinical Oncology · doi:10.31487/j.aco.2019.02.04 · Cited by 3
Sano, K., Hayashi, T., Suehara, Y., Hosoya, M., Takamochi, K., Kohsaka, S., Kishikawa, S., Kishi, M., Saito, S., Takahashi, F., et al. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.213 · Cited by 3
Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer
Li, H., Liu, C., & Wang, Y. (2022) · Future Oncology · doi:10.2217/fon-2021-1488 · Cited by 3
Spagnuolo, A., Muto, M., Monaco, F., Colantuoni, G., & Gridelli, C. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.24 · Cited by 3
Ren, Y., Chen, J., Mo, X., Yang, Q., Chen, P., Lu, G. X., Tan, H. W. S., Yi, J., Yu, Q., Kim, Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622126 · Cited by 3
Zeng, X.-X. I., Xian, K.-X., Wen, J.-L., Wang, Q.-Z., Wang, X., & Sun, L. (2025) · Hereditas · doi:10.1186/s41065-025-00492-7 · Cited by 2
MiR-1976 affects lung squamous cell carcinoma development by targeting NCAPH
Li, Y., Zhou, H., Yao, Y., & Fan, Z. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00990-4 · Cited by 2
Manolakos, P., Wang, Y.-B., Withycombe, J. S., Boccuto, L., & Ivankovic, D. S. (2025) · Biomedicines · doi:10.3390/biomedicines13092142 · Cited by 2
p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Wang, M., Bieging-Rolett, K. T., Kaiser, A. M., Brady, C. A., Lockhart, J. H., Ferreira, S., Nguyen, K. T., Rajeevan, A., Evans, S. A., Zhao, T., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0525 · Cited by 3
Self-citationNovel pyrrole-sulfonamide derivatives as EGFR inhibitors and radiosensitizers in lung cancer
El-Gazzar, M. G. M., Zahran, S. S., Ghorab, M. M., & El-Gazzar, M. G. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109173 · Cited by 2
Delasos, L., & Hassan, K. A. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01061 · Cited by 2
Zhu, C., Li, Y., Xu, H., Sun, L., Wei, Y., 马承娴, Chen, Q., & He, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02682-9 · Cited by 4
Metadata
- Authors
- Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Paik, P. K., Drilon, A., Hellmann, M. D., Reales, D. N., Benayed, R., Rusch, V. W., Kris, M. G., Chaft, J. E., Baselga, J., Taylor, B. S., Schultz, N., Rudin, C. M., Hyman, D. M., Berger, M. F., Solit, D. B., Ladanyi, M., & Riely, G. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Riely, Gregory J.
- ORCID
- Jordan, Emmet J.
- Kim, Hyunjae R.
- Arcila, Maria E.
- Chakravarty, Debyani
- Gao, JianJiong
- Kundra, Ritika
- Jonsson, Philip
- Jayakumaran, Gowtham
- Zehir, Ahmet
- Rekhtman, Natasha
- Ginsberg, Michelle S.
- Li, Bob T.
- Yu, Helena A.
- Paik, Paul K.
- Drilon, Alexander
- Hellmann, Matthew D.
- Reales, Dalicia N.
- Benayed, Ryma
- Rusch, Valerie W.
- Kris, Mark G.
- Chaft, Jamie E.
- Taylor, Barry S.
- Schultz, Nikolaus
- Rudin, Charles M.
- Hyman, David M.
- Berger, Michael F.
- Solit, David B.
- Ladanyi, Marc
- Riely, Gregory J.
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 596-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5482929
- OpenAlex
- W2603411876
- Cited by
- 643
- References
- 49
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 65 · 2023: 99 · 2022: 94 · 2021: 101 · 2020: 79 · 2019: 65 · 2018: 55 · 2017: 12
- FWCI
- 47.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, metastatic lung cancer, actionable mutations, targeted therapy, predictive biomarkers, drug response, STK11, Keap1, clinical benefit, molecular profiling
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adolescent, Adult, Aged, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Biomarkers, Tumor, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
